REGENXBIO Reports Third Quarter 2026 Financial Results and Operational Highlights

The Quick Take
RGX-202 BLA submission for Duchenne muscular dystrophy on track for Q1 2027, with potential accelerated approval in 2H 2027 Topline data from pivotal subretinal wet AMD studies, ATMOSPHERE® and ASCENT®, expected in Q4 2026 Phase IIb/III NAAVIGATE trial for diabetic retinopathy ongoing...
Ground Level News aggregates headlines from public feeds. This page shows a short summary only; the full article and all rights belong to PR Newswire M&A.
Related
Business
STAK Energy Signs Long-Term Agreement to Bring North Slope Natural Gas to Market
Agreement supports power development using previously stranded gas in northern Alaska ANCHORAGE, Alaska, Nov. 5, 2026 /PRNewswire/ -- STAK Energy Corporation…
Business
LA COMPAGNIE INTRODUCES YEAR-ROUND DIRECT BUSINESS CLASS SERVICE BETWEEN NEW YORK AND NICE
For the first time, the 100% Smart Business Class airline extends its New York–Nice service through the 2026–2027 winter season, offering the only direct…
Business
The RealReal Appoints Shar Dubey to Board of Directors
Former Match Group CEO Brings Deep Expertise in Technology, Digital Consumer Platforms and Scaling Global Businesses SAN FRANCISCO, Nov. 5, 2026 /PRNewswire/…
Local
NREF Announces Third Quarter 2026 Results, Provides Fourth Quarter 2026 Guidance
DALLAS, Nov. 5, 2026 /PRNewswire/ -- NexPoint Real Estate Finance, Inc. ("NREF" or the "Company") (NYSE: NREF) today reported its financial results for the…
